US regulatory approaches to chemistry, manufacturing, and controls for botanical drug products
- PDF / 83,582 Bytes
- 1 Pages / 595.28 x 793.7 pts Page_size
- 99 Downloads / 160 Views
MEETING ABSTRACT
Open Access
US regulatory approaches to chemistry, manufacturing, and controls for botanical drug products Rajiv Agarwal From 2012 Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM) Shanghai, China. 27-29 June 2012
Many botanical products are used widely in the United States. Depending on its labeling and intended use, a botanical product can be a food, a dietary supplement, and/or a drug. If a botanical product is intended for use in diagnosing, mitigating, treating, or curing disease, it is a drug under the Food, Drug, and Cosmetic Act and is subject to applicable drug regulations. The CDER Guidance on Botanical Drug Products defines the term “Botanical” as a finished, labeled product that contains drug substance from plant origins, which may include plants or plant parts, algae, macroscopic fungi, and combinations thereof. The term does not include highly purified substances or chemically modified substances derived from botanical sources. This presentation provides an overview of the Chemistry, Manufacturing, and Controls (CMC) information recommended to support the clinical studies of a botanical drug product under an investigational new drug application (IND) in the United States. Veregen (sinecatachins) ointment1 was the first botanical drug product approved by the FDA since publication of the Botanical Guidance (2004)2. While the Guidance gave a general pathway for IND submissions, it was silent on the requirements for NDA approval. A “CDER Botanical Guidance rewrite Working Group” has been established and the work is in progress to consolidate the FDA’s current scientific and regulatory thinking in the future Botanical Guidance.
References 1. Chen ST, Dou J, Temple R, Agarwal R, Wu K-M, Walker S: New therapies from old medicines. Nature Biotech 2008, 26(10):1077-1083. 2. Guidance for Industry. Botanical Drug Products (US FDA, June 2004). [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM070491.pdf ]. doi:10.1186/1479-5876-10-S2-A40 Cite this article as: Agarwal: US regulatory approaches to chemistry, manufacturing, and controls for botanical drug products. Journal of Translational Medicine 2012 10(Suppl 2):A40.
Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color figure charges
Published: 17 October 2012
• Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution
Correspondence: [email protected] Office of New Drug Quality Assessment, Office of Pharmaceutical Science, US Food and Drug Administration, 10903 New Hampshire AvenueSilver Spring, MD 20903, USA
Submit your manuscript at www.biomedcentral.com/submit
© 2012 Agarwal; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestri
Data Loading...
